Skip to main content
OpenTrials
Completed

NCT Number: NCT05224037

Comparative Efficacy of Liver Fibrosis and Steatosis Assessment With Fibroscan and iLivTouch

This study is aimed to compare the results and operating characteristics of liver stiffness measurement with the use of Fibroscan (EchoSens, France) and iLivTouch (Wuxi Hisky Medical Technologies Co., China) in patients with chronic liver diseases.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Federal State Budgetary Scientific Institution "Federal Research Centre of Nutrition, Biotechnology

Moscow, 115446, Russia

About this study

This is prospective comparative trial to assess diagnostic characteristics of non-invasive methods of liver fibrosis and steatosis assessment based on the measurement of liver stiffness. The null hypothesis is that novel device, iLivTouch FT100/FT200 and standard probe allows to obtain similar results of liver stiffness and controlled attenuation parameter compared to FibroScan 530 and probes M+ and XL+ in patients with chronic liver diseases. According to the study protocol, standard examination will be performed to eligible subjects on the same day with the use of both devices. At least 10 measurements will be performed with the use of each device to each subject after overnight fasting. The medians of liver stiffness and controlled attenuation parameter measurements, their interquartile range, success rate of measurements and related interpretations of the results (grades of liver fibrosis and steatosis) will be compared. To assess the variability of the results, demographic data (age, biological sex, ethnicity) will be collected; weight and height of the subjects will be measured on the day of examination. Medical history of the subjects will be examined to extract data, confirming the presence of chronic liver diseases and ensure eligibility.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • willingness to participate on the basis of the signed informed consent form;
  • availability of the medical records

Exclusion criteria

  • pregnancy and breastfeeding;
  • narrow intercostal spaces making standard examination of the liver stiffness possible;
  • extreme obesity, in cases when amount of the fat tissue in right lower part of chest makes impossible to perform measurements;
  • ascites;
  • focal lesions of the liver (including, but not limited to liver cancer or metastases of cancer regardless of their origin, parasitic invasions, cysts) in projection of the measurements;
  • impossibility to perform evaluation with both devices due to any reasons;
  • any health-related conditions of a subject that put him/her at risk in case the procedures required per study protocol are performed or making him/her ineligible on the discretion of the investigator

Treatment and study plan

iLivTouch

Diagnostic Test

Eligible subjects will undergo liver stiffness and controlled attenuation parameters examination with two devices on the same day

Other names: FibroScan

Primary outcomes

  1. Liver stiffness

    Time frame: Study day 1

    Single assessment (Median by at least 10 measurements) of the liver stiffness in kilo pascals will be performed during examination of the subject

  2. Controlled attenuation parameter

    Time frame: Study day 1

    Single assessment (Median by at least 10 measurements) of the controlled attenuation parameter in kilo pascals will be performed during examination of the subject

Secondary outcomes

  1. Interquartile range of liver stiffness

    Time frame: Study day 1

    Single assessment (interquartile range by at least 10 measurements) of the liver stiffness in kilo pascals will be performed during examination of the subject

  2. Interquartile range of the controlled attenuation parameter

    Time frame: Study day 1

    Single assessment of interquartile range of the controlled attenuation parameter (by at least 10 measurements) in kilo pascals will be performed during examination of the subject

  3. Success rate

    Time frame: Study day 1

    Success rate (a quotient of division of number of successful measurement on the total of number of measurements performed during examination of a subject) with iLivTouch and Fibroscan

  4. Stage of liver fibrosis

    Time frame: Study day 1

    stage of liver fibrosis according to the liver stiffness and manufacturers instruction on the interpretation of the results of iLivTouch and FibroScan

  5. Stage of steatosis of the liver

    Time frame: Study day 1

    stage of liver fibrosis according to the measurement of the controlled attenuation parameter obtained during examination of a subject and manufacturers instruction on the interpretation of the results of iLivTouch and FibroScan

Sponsors and collaborators

Lead sponsor

Federal State Budgetary Scientific Institution

Other Gov

Registry information

Official study title

Comparative Efficacy of Liver Fibrosis and Steatosis Assessment With Fibroscan and iLivTouch in Patients With Chronic Liver Diseases

Acronym: OGIG-01-22-LF

Important dates

Study start
2022
Primary completion
2022
Study completion
2022
First posted
Feb 4, 2022
Registry last updated
Apr 11, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.